Xenon Stock Rises 12% in the Past Month on Pipeline Progress
Xenon Pharmaceuticals (XENE) shares have climbed nearly 12% over the past month due to significant progress in its lead epilepsy candidate, azetukalner, and promising early-stage results from its non-opioid pain programs. The company also reported better-than-expected third-quarter 2026 results and maintains a strong financial position with $1.15 billion in cash, expected to fund operations into 2029. Despite a voluntary pause in new patient enrollment for some psychiatric studies due to adverse events, investor optimism is high as the company advances multiple clinical trials and anticipates key milestones.
Xenon Stock Rises 12% in the Past Month on Pipeline Progress
Xenon Pharmaceuticals (XENE) shares have increased by 11.9% over the past month, driven by advancements in its epilepsy candidate, azetukalner, positive early-stage results from non-opioid pain programs, and a strong financial position with $1.15 billion in cash. The company submitted an NDA for azetukalner for focal onset seizures and plans further phase III studies, while also reporting positive phase I data for its pain candidates XEN1701 and XEN1120. Despite a voluntary pause in new patient enrollment for some psychiatric studies due to adverse events, investor optimism remains high due to expected clinical milestones and sufficient funding into 2029.
How Wider Losses At Xenon Pharmaceuticals (XENE) Have Changed Its Investment Story
Xenon Pharmaceuticals reported wider losses in Q3 2026, with a net loss of US$110.44 million and a nine-month loss of US$323.47 million, underscoring its reliance on equity funding for its R&D pipeline. The company also announced an ESOP-related shelf registration for 300,000 common shares, raising concerns about future dilution for shareholders. Despite the increased losses, the immediate clinical catalysts for its azetukalner program remain, though funding risk and commercialization plans are now more prominent investment considerations.
How Xenon Pharmaceuticals Inc. (XENE) Affects Rotational Strategy Timing
This article analyzes Xenon Pharmaceuticals Inc. (NASDAQ: XENE) using AI models to develop three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. It highlights a strong sentiment across all horizons supporting an overweight bias, but notes that a breakdown is underway with elevated downside risk. The report provides specific entry, target, and stop loss levels for each strategy based on multi-timeframe signal analysis.
Xenon Pharmaceuticals (XENE) Could Be 43% Undervalued After Q3 Loss And Share Registration
Xenon Pharmaceuticals (XENE) reported a Q3 2026 net loss of US$110.44 million and a share registration, yet analysts at Simply Wall St believe the stock is 43% undervalued with a fair value of $72.43. This optimistic outlook is tied to its late-stage epilepsy program, azetukalner, which is expected to drive significant revenue growth upon approval. However, the article also notes risks such as potential disappointment in late-stage data or safety concerns.
Xenon Pharmaceuticals (XENE) Stock Looks Above Fair Value Next To Book Value
Xenon Pharmaceuticals (XENE) has seen a 36.2% gain over the past three years, driven by drug pipeline updates. The stock trades at a Price-to-Book (P/B) ratio of 3.2x, which is above the biotech industry average of 1.8x, suggesting investors are paying a premium for its pipeline, including an FDA filing for azetukalner and multiple pain candidates in Phase 2. While some analysts believe the stock is undervalued by as much as 55%, investors should consider whether the neuroscience portfolio and future funding needs justify its current valuation relative to its book value.
Xenon (XENE) Q3 2026 Earnings Call Transcript
Xenon Pharmaceuticals (XENE) reported its Q3 2026 financial and operational results, highlighted by the submission of its New Drug Application for azetukalner in focal seizures and accelerated timelines for key clinical programs. The company maintained a strong cash position of $1.2 billion, funding operations into 2029, and discussed advancements in its epilepsy, neuropsychiatry, and pain pipelines, including positive Phase 1 data for non-opioid pain candidates. Management expressed confidence in azetukalner's commercial potential and its strategy to expand its use earlier in the treatment paradigm.
XENE: AZK heads toward potential launch as psychiatry data and phase II pain studies approach
Xenon Pharmaceuticals Inc. (XENE) is progressing towards the potential launch of AZK, with an NDA submitted and launch preparations underway. The company has significant cash and securities, projected to fund operations into 2029. Key upcoming events include X-NOVA2 data in December and the advancement of pain candidates into phase II studies.
Xenon Reports Q3 2026 Financial Results and Provides Business Update
Xenon Pharmaceuticals Inc. reported its Q3 2026 financial results, highlighting significant progress with its lead drug candidate, azetukalner, including an NDA submission for focal seizures and completion of enrollment for a major depressive disorder study. The company also announced positive Phase 1 data for its non-opioid pain programs, XEN1701 and XEN1120, which are expected to advance to Phase 2 studies. Financially, Xenon ended the quarter with $1.2 billion in cash, projecting a runway into 2029, despite an increased net loss compared to the previous year.
Xenon Reports Q3 2026 Financial Results and Provides Business Update
Xenon Pharmaceuticals reported its Q3 2026 financial results, highlighting significant progress in its azetukalner development program, including an NDA submission for focal seizures to the FDA. The company completed enrollment in the X-NOVA2 study for MDD, with topline data expected in December 2026, and plans to initiate Phase 2 studies for its non-opioid pain programs, XEN1701 and XEN1120, in H1 2027. Xenon maintains a strong financial position with $1.2 billion in cash, cash equivalents, and marketable securities, providing a cash runway into 2029.
How Positive Pain Trial Data At Xenon Pharmaceuticals (XENE) Has Changed Its Investment Story
Xenon Pharmaceuticals (XENE) recently reported positive Phase 1 trial data for its pain drugs XEN1701 and XEN1120, showing strong NaV1.7 receptor occupancy and mild side effects, which supports advancing to Phase 2 acute pain studies in early 2027. While these results deepen the company's pain pipeline, the primary near-term value driver remains azetukalner in late-stage epilepsy trials. The company, currently loss-making, needs successful late-stage readouts and future payer support to achieve self-funding, with analysts projecting significant revenue and earnings by 2029.
Behavioral Patterns of XENE and Institutional Flows
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shows strong sentiment across all time horizons, supporting an overweight bias despite elevated downside risk. AI-generated trading strategies include long position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss zones. Multi-timeframe signal analysis also provides strong signals for near-term, mid-term, and long-term periods.
Xenon to Present at Upcoming Investor Conferences
Xenon Pharmaceuticals Inc. announced its participation in four upcoming investor conferences during the fourth quarter of 2026. The neuroscience-focused biopharmaceutical company will hold fireside chats at the Guggenheim 3rd Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, 2026 Jefferies Global Healthcare Conference, and 9th Annual Evercore Healthcare Conference. Details and webcast information for these presentations will be available on the Investors section of Xenon's website.
Xenon to Report Q3 2026 Financial Results on November 9,
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced it will report its third quarter 2026 financial results and provide a business update on Monday, November 9, 2026, after the close of U.S. financial markets. The company will host a presentation at 4:30 PM EST, accessible via webcast and dial-in. Xenon is a neuroscience-focused biopharmaceutical company developing therapeutics for epilepsy, major depressive disorder, and bipolar depression, with its lead molecule azetukalner in late-stage clinical development.
Xenon Pharmaceuticals (XENE) Stock Price, Chart & Analysis
This article provides an in-depth analysis of Xenon Pharmaceuticals (XENE) stock, including its latest price, market capitalization, key financial figures, and quality score. It covers aspects like revenue growth, dividend policy, balance sheet strength, and analyst expectations. The analysis also includes valuation insights and comparisons with sector peers.
Xenon Pharmaceuticals Inc (XP0.SG) Seasonal returns chart
The article provides a seasonal returns chart for Xenon Pharmaceuticals Inc (XP0.SG) on Yahoo Finance. It displays the average monthly price return for the company between 2018 and 2026. The page also includes current stock data and related financial information.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to nine new non-officer employees, totaling 24,250 share options and 14,250 restricted share units (RSUs). These grants, approved by the Compensation Committee, are material inducements for employment under Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $37.54 and vest over four years, while RSUs also vest over four years, both subject to continued service.
Nine new Xenon employees get options to buy shares for $37.54 each
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) announced it granted equity inducement awards to nine new non-officer employees, effective October 29, 2026. These awards include 24,250 share options with an exercise price of $37.54 per common share and 14,250 restricted share units (RSUs). Both the options and RSUs vest over four years, subject to continued service, as a material inducement for their employment under Nasdaq Listing Rule 5635(c)(4).
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals announced the granting of inducement awards to three new employees, consisting of stock options and restricted stock units, to comply with Nasdaq Listing Rule 5635(c)(4). The grants, approved by the Compensation Committee, are an incentive for the employees to join the company and are subject to vesting over a four-year period.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to nine new non-officer employees, totaling 24,250 share options and 14,250 restricted share units (RSUs). These grants, with an effective date of October 29, 2026, were approved by the Compensation Committee as material inducements for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $37.54 and vest over four years, while the RSUs also vest over four years, both subject to continued employment.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to nine new non-officer employees, consisting of 24,250 share options and 14,250 restricted share units (RSUs). These grants, approved by the Compensation Committee, were made as material inducements for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $37.54 per common share and vest over four years, while the RSUs vest over four years on the anniversaries of the grant date.
Xenon Announces Positive Phase 1 and New Preclinical Data
Xenon Pharmaceuticals Inc. announced positive Phase 1 study results and new preclinical data for XEN1701 and XEN1120, supporting their advancement to Phase 2 proof-of-concept studies in acute pain. The data, presented at IASP 2026, show that both compounds achieved their target profiles, were generally well-tolerated, and demonstrated significant pain reduction in preclinical models. Phase 2 studies for these novel non-opioid pain therapeutics are expected to begin in the first half of 2027.
Form 4 Xenon Pharmaceuticals Inc.: Ian Mortimer (Director, PRESIDENT & CEO) For: 30 September
This article reports on a Form 4 filing for Xenon Pharmaceuticals Inc., detailing transactions by Ian Mortimer, who serves as a Director, President, and CEO. The filing pertains to activities as of September 30. The publication date is listed as October 25, 2026.
Form 4 Xenon Pharmaceuticals Inc.: Thomas Patrick Kelly (CFO) For: 30 September
This article reports on a Form 4 filing for Xenon Pharmaceuticals Inc., indicating a transaction by Thomas Patrick Kelly, the CFO, for September 30. The brief update was published on October 25, 2026, and provides no further details beyond the filing information.
Form 4 Xenon Pharmaceuticals Inc.: Ian Mortimer (Director, PRESIDENT & CEO) For: 30 September By Investing.com
This article reports on a Form 4 filing for Xenon Pharmaceuticals Inc., indicating a transaction by Ian Mortimer, who serves as Director, President, and CEO. The filing is specifically for the period ending September 30. The article is very brief and primarily serves as an announcement of the filing.
Xenon Pharmaceuticals Inc. (XENE) Options Chain
This article provides detailed options chain data for Xenon Pharmaceuticals Inc. (XENE) with a December 15, 2028 expiration. It lists both call and put options, including strike prices, last trade dates, last prices, bids, asks, changes, percentage changes, volumes, open interest, and implied volatility. The stock closed at $35.34 on October 23, 2026.
Xenon Pharmaceuticals Inc. Estimates – NASDAQ:XENE
This page on TradingView provides financial estimates and actuals for Xenon Pharmaceuticals Inc. (NASDAQ: XENE). Users can explore reported financial data, analyst estimates, and visualize trends across income statements, balance sheets, cash flow statements, and valuation metrics. It allows comparison of actual results with average, high, and low estimates.
Law firm investigates Xenon Pharmaceuticals after stock drops 31% on clinical trial pause
Wolf Popper LLP is investigating potential claims against Xenon Pharmaceuticals after the company's stock dropped 30.7% due to pausing new patient enrollment in clinical trials for neurological and psychiatric drugs. The pause was prompted by reports of neuropsychiatric adverse events. This investigation could lead to legal action, offering affected investors a chance to recover losses.
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. common stock. This follows a significant drop in Xenon's stock price after the company announced a voluntary pause in new patient enrollment for its clinical studies in MDD and bipolar depression due to neuropsychiatric adverse events. Investors who suffered losses are encouraged to contact Wolf Popper LLP.
Xenon Pharmaceuticals Inc. (XENE) Interactive Stock Chart
This page provides an interactive stock chart for Xenon Pharmaceuticals Inc. (XENE), showing its performance with real-time price updates and after-hours trading information. It also lists recent news articles related to XENE, covering topics such as depression trial setbacks, pipeline attractiveness, and inducement grants. The stock closed at $35.95 on October 21, 2026.
Wells Fargo sets USD 64 target for Xenon Pharmaceuticals stock
Wells Fargo maintained a Buy rating and set a USD 64 price target for Xenon Pharmaceuticals (XENE) stock, which was trading at EUR 31.10. This valuation comes as Xenon advances its lead drug candidate, azetukalner, through Phase 3 studies for epilepsy and neuropsychiatric conditions, supported by a substantial cash position of USD 1.2 billion. The company reported a second-quarter loss but continues to progress with pipeline milestones despite a clinical setback in its depression program.
Xenon grants 28,350 awards: target for Xenon Pharmaceuticals stock is USD 73.00
Xenon Pharmaceuticals recently granted 28,350 awards (17,850 options and 10,500 restricted share units) to new employees, indicating ongoing hiring. Guggenheim initiated coverage with a USD 73.00 price target, reflecting confidence in the company's clinical and regulatory progress, particularly for azetukalner. Upcoming milestones include topline data from the X-NOVA2 study in Q1 2027 and the regulatory path for azetukalner in focal seizures, which are crucial for the stock's valuation.
Xenon grants 28,350 awards: target for Xenon Pharmaceuticals stock is USD 73.00
Xenon Pharmaceuticals granted 28,350 awards (17,850 options and 10,500 restricted share units) to eight new employees on October 2, 2026, coinciding with Guggenheim setting a USD 73.00 target for the stock on October 6, 2026. This move suggests ongoing hiring and links the company's valuation to the clinical and regulatory progress of its drug azetukalner, particularly with topline data from X-NOVA2 expected in Q1 2027. The company's adjusted earnings per share for Q2 2026 improved against consensus estimates, and its market capitalization was USD 3.2 billion as of October 16, 2026.
Is Xenon Pharmaceuticals (XENE) Undervalued On Its Epilepsy Pipeline Or Already Priced In?
Xenon Pharmaceuticals (XENE) has experienced a significant price decline recently, leading to questions about whether it is undervalued. The company's epilepsy program, particularly azetukalner, is seen as a key driver for potential future revenue, with one narrative suggesting a 54% undervaluation. However, risks remain regarding late-stage data and safety concerns, prompting investors to weigh potential upsides against these warning signs.
Form 4 Xenon Pharmaceuticals Inc.: Thomas Patrick Kelly (CFO) For: 15 October
This article reports on a Form 4 filing for Xenon Pharmaceuticals Inc. concerning Thomas Patrick Kelly, the CFO. The filing is dated for October 15.
Vesting adds 7,500 shares for Xenon Pharmaceuticals (XENE) CFO; direct holdings total 22,500.
Xenon Pharmaceuticals CFO Thomas Patrick Kelly acquired 7,500 common shares as 7,500 restricted share units vested on October 15, 2026. This award, granted on October 15, 2025, vests 25% annually over four years, starting from October 15, 2026. Following this transaction, Kelly directly holds 22,500 common shares in the company.
Xenon Pharmaceuticals CFO Kelly Thomas Patrick Converts 7,500 RSUs into Common Shares
Xenon Pharmaceuticals CFO Kelly Thomas Patrick has converted 7,500 restricted share units (RSUs) into common shares on October 15, 2026. This transaction is part of an RSU award granted in October 2025, which vests 25% annually over four years. Following this conversion, Patrick now directly holds 22,500 common shares of the company.
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Xenon Pharmaceuticals (XENE) faces investor concern after temporarily pausing enrollment in its late-stage depression trials due to unexpected neurological and psychiatric side effects from its lead asset, azetukalner. Despite this setback, the company's epilepsy program for azetukalner, which has shown positive results and is under FDA review, remains a key growth driver. Xenon also has other early-stage candidates for pain, and expects to release topline results for its X-NOVA2 depression study in Q1 2027.
Xenon grants 28,350 awards as Xenon Pharmaceuticals stock is valued at USD 3.3 billion
Xenon Pharmaceuticals granted 28,350 equity awards on October 2, 2026, as the company's stock is valued at USD 3.3 billion. This comes after the submission of an application to the FDA for azetukalner in focal seizures on September 17, 2026, and continued hiring efforts. The company expects topline data from its X-NOVA2 major depressive disorder study in Q1 2027.
Xenon Pharmaceuticals stock hits 52-week low at 35.04 USD
Xenon Pharmaceuticals (XENE) stock has dropped to a 52-week low of $35.04, reflecting a significant decline over the past year. Despite the current undervaluation and oversold RSI, analysts maintain a bullish outlook with price targets ranging from $46 to $90. The company recently paused Phase III trials for MDD and BPD due to adverse events, leading several analyst firms to adjust their price targets while largely maintaining Buy ratings.
Xenon Pharmaceuticals stock hits 52-week low at 35.04 USD By Investing.com
Xenon Pharmaceuticals Inc. (XENE) stock has dropped to a 52-week low of $35.04, reflecting a 39% loss over the past six months and a 13.31% decline over the year. Despite the recent downturn and a voluntary pause in some Phase III trials due to adverse events, analysts maintain a bullish outlook with price targets up to $90, and InvestingPro data suggests the stock is currently undervalued. The company's X-NOVA2 trial for major depressive disorder is still on track for results in Q1 2027.
Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Call
Xenon Pharmaceuticals reported strong Q2 2026 financial results, with $1.2 billion in cash, extending operations funding into 2029. The company is on track to submit a New Drug Application (NDA) for azetukalner (AZK) for focal seizures this quarter, following a successful pre-NDA meeting with the FDA. Xenon is also advancing AZK through five additional Phase 3 studies for other epilepsy and neuropsychiatry indications, and expanding its pain programs with multiple Phase 1 studies for novel non-opioid therapeutics.
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced an investigation into Xenon Pharmaceuticals Inc. (NASDAQ: XENE) following a significant 30.7% drop in share price. This decline occurred after Xenon voluntarily paused enrollment for new patients in its clinical studies for major depressive disorder and bipolar depression due to neuropsychiatric adverse events. SBS is investigating whether the company made false or misleading statements and encourages affected shareholders to participate in the fraud investigation.
Alpha Buying: 4 Biotech Stocks Insiders Are Betting On
This article highlights four biotech companies—Xenon Pharmaceuticals (XENE), Relmada Therapeutics (RLMD), NeOnc Technologies Holdings (NTHI), and MAIA Biotechnology (MAIA)—where executives and insiders have made significant stock purchases. These companies are developing treatments for various conditions including epilepsy, bladder cancer, brain cancer, and lung cancer. The author emphasizes that insider buying, especially by CFOs and those directly involved in drug development, can be a strong signal of confidence despite the inherent risks in clinical biotech.
Is Xenon Pharmaceuticals (XENE) Undervalued After Its Sharp Three Month Pullback?
Xenon Pharmaceuticals (XENE) has experienced a significant stock price decline of 39.06% over the last month and 48.69% over the past three months. Despite this pullback, a common valuation narrative suggests the company is 52% undervalued, with a fair value estimated at $75.69, largely
Is Xenon Pharmaceuticals (XENE) Undervalued After Its Sharp Three Month Pullback?
Xenon Pharmaceuticals (XENE) has experienced a significant share price decline over the past three months, prompting questions about whether it is now undervalued. Despite the recent pullback, the company is seen by some as 52% undervalued, with a fair value pegged at $75.69, largely due to ambitious long-term expectations for its drug azetukalner. However, risks remain, particularly concerning potential disappointments in late-stage data or broader neuropsychiatric safety concerns.
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Wolf Popper LLP is continuing its investigation into potential claims against Xenon Pharmaceuticals Inc. on behalf of investors who suffered losses. This follows a significant drop in Xenon's stock price after the company announced a voluntary pause in new patient enrollment for its clinical studies of azetukalner due to neuropsychiatric adverse events. The firm encourages affected investors to contact them to discuss the ongoing investigation.
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
Wolf Popper LLP is continuing its investigation into potential claims for investors in Xenon Pharmaceuticals Inc. (NASDAQ: XENE). This follows a significant 30.7% drop in Xenon's stock price after the company announced a voluntary pause in new patient enrollment for clinical studies of its lead drug candidate, azetukalner, for MDD and bipolar depression due to neuropsychiatric adverse events. Investors who suffered losses are encouraged to contact the firm for more information.
Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD
Xenon Pharmaceuticals Inc. (XENE) stock has reached a 52-week low of $36.06, down 34% over the past six months, despite InvestingPro analysis suggesting it is undervalued. This decline follows the company's voluntary pause in Phase III trials for major depressive disorder and bipolar disorder due to neuropsychiatric adverse events. Several financial firms have adjusted their price targets and ratings, with Deutsche Bank downgrading the stock to Hold due to safety concerns.
Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD
Xenon Pharmaceuticals Inc. (XENE) stock has reached a 52-week low of $36.06, a significant drop from its high of $72.66 and a 34% decline over the past six months. This downturn follows the company's decision to pause patient enrollment in Phase III trials for major depressive disorder and bipolar disorder due to neuropsychiatric adverse events. Despite the stock's performance, InvestingPro analysis suggests it is currently undervalued, with several firms maintaining Buy ratings while Deutsche Bank downgraded it to Hold due to safety concerns.